We advised the WSE-listed Genomtec S.A. on its prospect-free IPO

23.06.2023 Case studies Capital Markets

tygrys

We advised the WSE-listed Genomtec S.A. on a prospect-free public offering of the company’s shares carried out under the accelerated bookbuilding procedure (ABB) and a related private placement of the company’s new issue shares.

The public offering comprised 1,237,000 series M new issue shares and 900,000 existing shares of the company, admitted to trading on the regulated market of the WSE, offered by its shareholder, Leonarto Funds SCSp. The shares offered by the shareholder were previously borrowed for this purpose from other shareholders of the company. The public offering was targeted at qualified investors and selected retail investors.

As part of the private placement, the company issued 400,000 N shares, which were subscribed for by Leonarto Funds SCSp in order to reinvest the funds raised from the sale of the company’s shares in the public offering (including the funds used to purchase part of the M shares by the shareholder).

The total value of the public offering and the private placement amounted to PLN 20,296,000.

We supported the company in all legal aspects of the transaction. The scope of advisory services included, in particular, advice on structuring the transaction, preparation and negotiation of transaction documentation (e.g. investment agreement, loan agreements, issue documentation), advice on fulfilment of the Company’s disclosure obligations and legal advice on the process of dematerialisation of new issue shares and admission of series M shares to trading on the regulated market of the WSE.

Bookkeeping for the shares offered in the public offering was entrusted to Dom Maklerski INC S.A.. In terms of Investor Relations, the company was also supported by cc group.

We would like to thank Genomtec S.A. and the other advisers involved in the transaction for their fruitful cooperation and trust.

The project supervised by Krzysztof Marczuk was managed by Michal Wielinski supported by Jakub Rowicki. The project team also included Michał Dunikowski.

Genomtec S A. is a technology company operating in the field of clinical diagnostics. It was founded in 2016 in Wrocław, Poland, with a vision of international expansion based on a unique mobile genetic diagnostics platform using a patented non-contact heating and detection system. The company, founded by a group of scientists with experience and competence in the fields of molecular biology and microsystems and photonics, has its headquarters and laboratories in Wrocław. Genomtec also has an office in the UK, where part of the international research and engineering team is located.

Lawyers involved in the project

8. Krzysztof Marczuk 772x1158

Krzysztof Marczuk

Partner
Attorney-at-law

Capital Markets

Krzysztof Marczuk
12. Michal Wielinski 772x1158

Michał Wieliński

Managing Associate
Attorney-at-law

Capital Markets | Mergers and acquisitions (M&A) | Corporate law

Michał Wieliński
9. Jakub Rowicki 772x1158

Jakub Rowicki

Senior Associate
Advocate

Capital Markets | Mergers and acquisitions (M&A)

Jakub Rowicki
18. Michal Dunikowski 1 772x1158

Michał Dunikowski

Associate
Tax Advisor

Capital Markets

Michał Dunikowski

You may also like

11.06.2024

GESSEL advises Inplus in the sale of Smart Factor to Cyclomedia

Cyclomedia, a global leader in providing highly accurate 360-degree street-level panoramas and 3D data enhanced with AI-driven analyses, announces the acquisition of Sma...

Case studies
GESSEL advises Inplus in the sale of Smart Factor to Cyclomedia

11.06.2024

We have advised on yet another LUX MED investments!

We have advised the LUX MED group on yet another investment - this time in Ortopedicum hospital in Cracow. Our comprehensive support included due diligence, work on t...

Case studies
We have advised on yet another LUX MED investments!
Wszystkie case studies

Do you want to be up to date?

Subscribe to the newsletter!

tygrys